GLPwatch
Papers (12034)
Page 171 of 201, ranked by citation count.
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in Prompting a Meaningful Improvement in Alcohol Use Disorder.
- La metformine comme stabilisateur de poids après l’arrêt du sémaglutide ?
- [The extra-glycemic effects of liraglutide: focus on cardiometabolic markers].
- Cardiovascular and brain effects of liraglutide in transthyretin amyloidosis (ATTR) mice models.
- Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis.
- Distinguishing among incretin-based therapies. Patient education and self-management.
- [Emerging GLP-1 analogues and dipeptidyl peptidase 4(DPP-4) inhibitors].
- GLP-1 receptor agonists in adolescent obesity: Incretin-based therapies during a sensitive developmental period.
- [GLP-1 receptor agonists : impact on diabetic kidney disease].
- The glucagon-like peptide-1 receptor agonist, Ex4, reduces intromission in sexually experienced male mice.
- Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol.
- Psychiatric Safety Signals of GLP-1 Receptor Agonists: A FAERS-Based Pharmacovigilance Study with Explainable Machine Learning.
- Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m<sup>2</sup>: A Target Trial Emulation.
- Safety of glucagon-like peptide-1 receptor agonists in neuroendocrine neoplasms.
- [Effects of exendin-4 on rat cardiomyocyte apoptosis early after severe scald injury].
- GLP-1R activation alleviated sepsis-induced cardiac dysfunction by modulating macrophage polarization via the STING/ P65 pathway.
- Non-Arteritic Ischaemic Optic Neuropathy Associated with Semaglutide Use.
- Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis.
- Impact of tirzepatide on systemic arterial stiffness assessed by cardio-ankle vascular index in individuals with obesity complicated by type 2 diabetes: A retrospective cohort study in Japan.
- Semaglutide as a potential neuroprotective agent for neurological and neurodegenerative disorders: Mechanisms, preclinical evidence, and translational challenges and opportunities.
- Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy-Based Cross-Sectional Survey.
- Rational construction of porous cobalt nanoparticle integrated nitrogen doped hollow carbon nanostructures for peptide agonist exendin-4 biosensing.
- In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, oral semaglutide did not increase CV events.
- GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder.
- Long-term effects of weight-reducing drugs in people with hypertension.
- Early cardiovascular-kidney-metabolic progression with tirzepatide: population definition and clinical interpretation.
- A new indication for semaglutide (Wegovy).
- [New data from the US-American Diabetes Congress. GLP-1 effect: more than reducing blood glucose].
- The efficacyand safety of once weekly injectable semaglutide (Ozempic) among patients with Type 2 diabete sintertiary care hospital: A Retrospective Study.
- Semaglutide attenuates autistic-like behaviors in BTBR mice through the shaping of gut microbiota.
- [Dulaglutide and liraglutide compared].
- Comparative evaluation of liraglutide plus metformin combination therapy versus metformin monotherapy in patients with type 2 diabetes mellitus: A retrospective clinical study.
- Semaglutide: new dawn for diabetics.
- Resmetirom and semaglutide: next-generation therapies for metabolic-associated steatohepatitis. Opportunities, challenges and issues.
- Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk.
- IDE-mediated GLP-1 degradation as the basis for designing long-acting and CNS-stable GLP-1 receptor agonists.
- Employee perceptions and experiences with tirzepatide treatment for obesity or overweight in the US: Insights from the PERCEPTIONS Survey.
- Liraglutide combined with dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice.
- Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial.
- Single-cell RNA sequencing reveals beneficial mechanisms of Exendin-4 in autoimmune uveitis.
- A validated, modifiable proteomic score from the EXSCEL trial predicts cardiovascular events in diabetes.
- Semaglutide and Exercise Synergy in Obesity: Preserving Muscle Mass and Uncovering Organ Crosstalk.
- Liraglutide for Adolescents with Obesity.
- [Is there life after teduglutide?]
- Late-stage generation of <sup>14</sup>C/<sup>3</sup>H-radiolabeled lysine residues via hydroformylation of peptides.
- [Indicators of diabetes mellitus after liraglutide, sitagliptin/metformin, linagliptin, and sitagliptin].
- Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.
- "Ozempic Limb": Understanding the Impact of Semaglutide on Prosthesis Use and Residual Limb Care in Individuals With Lower Limb Amputation.
- Optic disc edema during semaglutide therapy: case report and literature review.
- Too much of a good thing.
- Effects of acute GLP-1 analogue infusion on the glycemic and neurohormonal responses to meal test in non- hypoglycemic subjects after gastric bypass.
- Oral Semaglutide: Balancing Promising Therapeutics with Adverse Effects and Access Barriers.
- [Beta-cell function in the foreground. GLP-1 based therapy of type 2 diabetes].
- Papular granuloma annulare associated with tirzepatide: A case report.
- Acute Small Bowel Obstruction Induced by Tirzepatide (Mounjaro).
- Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity.
- Incretin effect is sufficient for glucose control in developing rats.
- Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial.
- [Therapeutic use and adverse events of incretin-related drugs].
- N-terminally modified GLP1R agonists drive G protein bias via extracellular loop 3 displacement.